Latest Period
Q1 2026
Security Snapshot
Voyager Therapeutics, Inc. - Common Stock (VYGR) Institutional Ownership
CUSIP: 92915B106
13F Institutional Holders and Ownership History from Q4 2015 to Q1 2026
Institutions Reporting
133
Shares (Excl. Options)
33,517,608
Price
$3.86
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- VYGR on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 33,517,608
- Total 13F value
- $129,396,422
- Portfolio coverage rank
- 0%
- Share change
- -278,289
- Value change
- -$1,386,132
- Number of holders
- 133
- Shares outstanding
- 59,625,213
- SEC-reported price per share
- $3.83
- Insider filing price
- $3.83
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- VYGR - Voyager Therapeutics, Inc. - Common Stock is tracked under CUSIP 92915B106.
- 133 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 124 to 133 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $132,696,702 to $129,396,422.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 133 institutions filings for Q1 2026.
Security key
92915B106
Latest holder period
Q1 2026
13F holders
133
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
VYGR full holder history
Voyager Therapeutics, Inc. SEC filings
Voyager Therapeutics, Inc. company facts
Voyager Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92915B106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
VYGR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 6.4% | $12,445,128 | 3,525,532 | BlackRock, Inc. | 31 Mar 2025 | |||
| ARMISTICE CAPITAL, LLC | 5.9% | -19% | $13,510,000 | -$1,930,000 | 3,500,000 | -12% | Armistice Capital, LLC | 31 Mar 2026 |
| INTEGRATED CORE STRATEGIES (US) LLC | 6.1% | $13,394,000 | 3,407,969 | Millennium Management LLC | 16 Jan 2026 |
As of 31 Mar 2026, 133 institutional investors reported holding 33,517,608 shares of Voyager Therapeutics, Inc. - Common Stock (VYGR). This represents 56% of the company’s total 59,625,213 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
49%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9.3% | 5,568,381 | -0.89% | 0% | $21,493,950 |
| ARMISTICE CAPITAL, LLC | 5.9% | 3,500,000 | -12% | 0.45% | $13,510,000 |
| MILLENNIUM MANAGEMENT LLC | 5.8% | 3,428,571 | +82% | 0.01% | $13,234,284 |
| Vestal Point Capital, LP | 5% | 3,002,936 | +104% | 0.32% | $11,591,333 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8% | 2,283,253 | 0% | 0% | $8,813,357 |
| Opaleye Management Inc. | 1.9% | 1,150,000 | -3.9% | 0.62% | $4,439,000 |
| Erste Asset Management GmbH | 1.8% | 1,095,141 | -8.4% | 0.04% | $4,238,196 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 1,049,978 | -7.5% | 0% | $4,054,437 |
| STATE STREET CORP | 1.6% | 948,226 | +1.3% | 0% | $3,660,152 |
| DIMENSIONAL FUND ADVISORS LP | 1.5% | 875,568 | -19% | 0% | $3,379,735 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.2% | 725,769 | 0% | 0% | $2,801,468 |
| MORGAN STANLEY | 1.1% | 681,711 | +25% | 0% | $2,631,404 |
| TWO SIGMA INVESTMENTS, LP | 1% | 615,660 | +176% | 0% | $2,376,448 |
| RENAISSANCE TECHNOLOGIES LLC | 0.97% | 578,024 | +95% | 0% | $2,231,173 |
| SPHERA FUNDS MANAGEMENT LTD. | 0.79% | 469,761 | +38% | 0.31% | $1,813,277 |
| GOLDMAN SACHS GROUP INC | 0.72% | 427,597 | +41% | 0% | $1,650,524 |
| DIADEMA PARTNERS LP | 0.71% | 423,642 | 0.73% | $1,635,258 | |
| NORTHERN TRUST CORP | 0.65% | 384,843 | +4.4% | 0% | $1,485,494 |
| CITADEL ADVISORS LLC | 0.61% | 364,664 | -34% | 0% | $1,407,603 |
| Fiduciary Trust Co | 0.56% | 334,397 | 0% | 0.02% | $1,290,772 |
| VANGUARD FIDUCIARY TRUST CO | 0.5% | 298,322 | 0% | 0% | $1,151,523 |
| JPMORGAN CHASE & CO | 0.46% | 276,867 | -15% | 0% | $1,071,474 |
| Altshuler Shaham Ltd | 0.46% | 273,925 | +34% | 0.02% | $1,057,351 |
| Point72 Asset Management, L.P. | 0.45% | 268,223 | +181% | 0% | $1,035,341 |
| ACADIAN ASSET MANAGEMENT LLC | 0.42% | 248,871 | +148% | 0% | $957,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
42
Latest
Q1 2026
Rows shown
1-25 of 42
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 33,517,608 | $129,396,422 | -$1,386,132 | $3.86 | 133 |
| 2025 Q4 | 33,757,964 | $132,696,702 | +$13,856,412 | $3.93 | 124 |
| 2025 Q3 | 30,211,033 | $141,111,279 | -$12,466,176 | $4.67 | 115 |
| 2025 Q2 | 33,174,673 | $103,118,305 | -$5,022,778 | $3.11 | 107 |
| 2025 Q1 | 34,693,910 | $117,319,204 | -$2,380,756 | $3.38 | 114 |
| 2024 Q4 | 34,577,603 | $195,996,497 | -$3,226,096 | $5.67 | 130 |
| 2024 Q3 | 35,034,671 | $205,128,146 | -$20,241,650 | $5.85 | 126 |
| 2024 Q2 | 38,132,801 | $301,619,686 | +$18,919,346 | $7.91 | 126 |
| 2024 Q1 | 35,559,200 | $331,104,508 | +$80,441,114 | $9.31 | 132 |
| 2023 Q4 | 26,951,934 | $227,544,384 | -$3,558,359 | $8.44 | 107 |
| 2023 Q3 | 27,251,321 | $211,188,846 | +$537,246 | $7.75 | 111 |
| 2023 Q2 | 26,875,646 | $307,720,979 | +$48,627,840 | $11.45 | 106 |
| 2023 Q1 | 23,842,811 | $183,821,375 | -$454,983 | $7.71 | 82 |
| 2022 Q4 | 23,994,562 | $146,245,078 | -$700,357 | $6.10 | 69 |
| 2022 Q3 | 24,135,758 | $142,907,865 | +$347,568 | $5.92 | 67 |
| 2022 Q2 | 24,076,804 | $142,325,318 | +$7,681,335 | $5.91 | 74 |
| 2022 Q1 | 22,468,342 | $171,312,566 | +$28,627,560 | $7.62 | 67 |
| 2021 Q4 | 18,846,543 | $51,240,128 | -$8,744,189 | $2.71 | 52 |
| 2021 Q3 | 22,241,759 | $58,623,539 | -$4,030,195 | $2.63 | 63 |
| 2021 Q2 | 23,442,885 | $96,817,913 | -$15,060,885 | $4.13 | 72 |
| 2021 Q1 | 26,694,047 | $125,738,812 | -$5,939,201 | $4.71 | 94 |
| 2020 Q4 | 27,690,758 | $198,031,668 | -$6,797,504 | $7.15 | 95 |
| 2020 Q3 | 28,071,762 | $299,694,014 | -$21,155,353 | $10.67 | 107 |
| 2020 Q2 | 29,835,329 | $376,668,426 | -$3,115,117 | $12.62 | 108 |
| 2020 Q1 | 30,273,841 | $276,907,152 | -$8,724,603 | $9.15 | 116 |